Monte Rosa Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies.

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.

RTW Investments

Cormorant Asset Management

Fidelity

Google Ventures

New Enterprise Associates

Cambridge Asset Management

Casdin Capital

HBM Healthcare Investments AG

Fidelity Management and Research Company

Aisling Capital

Amzak Health Investors

Avoro Capital Advisors

Today we share our second quarter 2024 financial results and corporate update. View the full press release here: https://bit.ly/3WDjih9

Step into the future with Monte Rosa's dynamic Data Sciences team! #DataSciences #AI #Biotech

We’re pleased to share this brand new scientific review of VAV1 published in Trends in Immunology, highlighting the therapeutic potential of novel approaches targeting VAV1 for autoimmune diseases, including our VAV1 molecular glue degrader MRT-6160. 

Read the scientific review here: https://bit.ly/4c6BO6Z

Every year Monte Rosa welcomes the brilliant scientists of tomorrow. Their curiosity, innovation, and enthusiasm help shape our culture. Learn more about the Monte Rosa Internship experience. #NationalInternDay #Biotech

Starting off the summer with good times and great people. 
#Summer #GoodTimes

Join our CEO Markus Warmuth next week for a fireside chat at the virtual UBS TPD day. Learn more here: https://bit.ly/3zuVS5I

Domain Not Resolving

Apple Mobile Web Clips Icon

HSTS

DNSSEC

Amazon

LetsEncrypt

nginx

jsDelivr

U.S. Server Location

Yoast SEO Premium

Chief Financial Officer

Ajim Tamboli

Chief Medical Officer

Filip Janku

Chief Executive Officer

Markus Warmuth

Chief Scientific Officer

Owen Wallace

Engineering

Philip Nickson

Chief Technology Officer

Sharon Townson

Human Resources

Jennifer Champoux

Director of Biology/ Head of Translational Drug Discovery (Boston)

Agustin Chicas

Senior Director, Immuno Oncology

Alison Paterson

Senior Scientist I

Bradley DeMarco

Alexander Mayweg

Christine Siu

Ali Behbahani

Chandra Leo

Andrew Schiff

Debora Bonenfant

Director, Proteomics

Jullian G. Jones

Chief Business Officer

Chief Operating Officer

Director of Drug Discovery

John Castle

Chief Data Scientist

Biotechnology Companies With More Than 10 Employees (Top 10K)

Biotechnology Public Companies With More Than 10 Employees

Therapeutics Companies With More Than 50 Employees

Europe, Middle East, and Africa (EMEA) Companies With More Than 50 Employees (Top 10K)

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond.

Post-IPO Equity - Monte Rosa Therapeutics

Series C - Monte Rosa Therapeutics

Series B - Monte Rosa Therapeutics

Series A - Monte Rosa Therapeutics

Basel

Basel-Stadt

Switzerland

Europe

Why Is Monte Rosa Therapeutics Stock Surging On Monday?

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics files IND application for molecular glue degrader MRT-6160

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 ...

Monte Rosa Therapeutics’ $100 Million Underwritten Public Offering

Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Monte Rosa's valuation gap to narrow, says Piper Sandler in new stock rating

A platform for discovering and developing drugs that degrade proteins relevant to diseases by identifying protein targets and designing molecules with high potency and selectivity.

Uses AI to identify degrons in proteins for targeted degradation.

A collection of molecular glue degraders designed to target and degrade disease-relevant proteins.

A suite of assays for discovering, optimizing, and advancing MGDs as clinical candidates.

Development of MGDs targeting proteins in cancer, autoimmune, and inflammatory diseases.

Guidelines for the use of investigational drugs outside of clinical trials.

Germany

South Korea

Asia

United States

North America

Sweden

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

news impact assignment basic	general
public peers	general	Sep 3, 2024 11:51 PM	d046f656
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 3, 2024 11:54 PM	7c23962e
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	712facff
crunchbase profile	general	Nov 25, 2024 10:32 AM	dc22d3a4
li profile	general	Sep 3, 2024 11:51 PM	2f394a5d
translate crunchbase fundingrounds	general	Nov 25, 2024 4:25 PM	eedaba7d
peers	general	Sep 3, 2024 11:51 PM	d3cbf57a
news basic	general	Sep 3, 2024 11:51 PM	116ae9bb
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:MONTEROSATX

Monte Rosa Therapeutics

Last Close

8.35

22/11 21:00

Market Cap

238.49M

Beta: -

Volume Today

327

Avg: -